Recently, Beijing Tongren Hospital Affiliated to Capital Medical University completed the fourth operation of MICOF independently developed and produced by our company. It marks the successful industrialization of the Michel artificial cornea with completely independent intellectual property rights, which will make millions of Chinese patients with corneal blindness hopeful to see light again.
Ms. Wang, a 47 year old patient, had tears and pain in her eyes caused by pesticides. However, due to the limited local medical level and the lack of professional eye care knowledge, she only dropped eye drops under the guidance of doctors in the local health center without further treatment.
Ms. Wang took photos before operation
As the days passed, Ms. Wang's eyesight was declining day by day. However, in order not to worry her family, Ms. Wang kept silent about her eyesight problems. It was not until one day that Ms. Wang fell down when she stepped down the steps that her family knew the truth. At that time, Ms. Wang could hardly see.
The situation was urgent. Ms. Wang's daughter, who contacted Microkpro this time, quickly took her mother to the health center. When she saw Ms. Wang's situation, the doctor said, "go to the hospital in Beijing!"
The doctor is examining Ms. Wang
It happened at this time that Ms. Wang's daughter saw the news of MICOF on the Internet, so she hurried to call for consultation and learned that her mother could use Michel's artificial cornea and have surgery in Beijing Tongren Hospital. Ms. Wang's daughter was very excited.
At present, Ms. Wang's first stage operation has been completed. I feel good and look forward to the second stage operation in three months.
Ms. Wang took photos at 9:00 the next day after phase I operation
Keratopathy is the second most common blindness in the world. In China, about 4million people with corneal blindness are waiting for the opportunity of vision restoration. At the same time, the shortage of donor cornea is very serious. Although no official organization in China has counted the amount of cornea donation, it is mentioned in the consensus of cornea transplantation experts 2015 of the cornea disease group of the ophthalmology branch of the Chinese Medical Association that the number of cornea transplantation completed in China is about 5000 every year. What is more worrying is that due to rejection, about 15% of them are blind and conventional keratoplasty can not succeed. Artificial cornea implantation is their only choice.
However, at present, only the United States has relatively mature artificial cornea products, and China is a blank in the field of artificial cornea. In the face of the universality of weak global research and development foundation of artificial cornea, China must complete the independent research and development of artificial cornea if it wants to fill the huge gap of cornea demand at home and abroad.
Therefore, the Michal medical R & D team began to develop MICOF. After 24 years of unremitting efforts, the MICOF was launched. In December, 2021, the product passed the review by the medical device technical evaluation center of the State Drug Administration and obtained the registration license of class III medical devices.
MICOF is an artificial cornea developed and produced in combination with the eye characteristics of corneal blindness patients and China's national conditions. It is made of artificial materials and does not need donor cornea. It will not lead to operation failure due to immune rejection after transplantation, which will help to alleviate the current situation of scarce corneal donors in China.
MICOF is suitable for patients with bilateral corneal blindness who are difficult to succeed in corneal transplantation, including corneal transplantation failure, severe keratoconjunctival scar vascularization caused by chemical injury, thermal burn, explosion injury, etc., eyelid atresia, serious autoimmune diseases (such as Stevens Johnson syndrome and cicatricial pemphigoid), corneal blindness caused by end-stage dry eye, etc, The product provides a new way for the clinical treatment of patients with contraindications to traditional corneal transplantation, breaks the "magic spell" of high-risk transplant patients with no medicine, and realizes the breakthrough of zero domestic artificial cornea.
The reason why MICOF can achieve success in the field of artificial cornea transplantation is due to "innovation and change", and its scientific research value is highly valued, because it is not a "curve overtaking" in the process of following the research ideas of developed countries, but a scientific research achievement with original significance in the world from concept to application. It is believed that this innovative product can bring light and hope to more patients with corneal diseases.